Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882206 | 1.00 | TSHR (0.52) | TSHRHCAR3ALDH1A1STAT3CASP6 | |
| SCHEMBL3500826 | 0.88 | KMT2A (0.51) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL3500828 | 0.88 | KMT2A (0.51) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL2536459 | 0.86 | STAT3 (0.54) | TSHRALDH1A1STAT3LMNARAB9A | |
| SCHEMBL2536457 | 0.86 | STAT3 (0.54) | TSHRALDH1A1STAT3LMNARAB9A | |
| SCHEMBL1013072 | 0.85 | STAT3 (0.53) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL1013073 | 0.85 | STAT3 (0.53) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL24358978 | 0.84 | STAT3 (0.52) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL4956345 | 0.84 | STAT3 (0.52) | ALDH1A1STAT3LMNARAB9A | |
| SCHEMBL4876750 | 0.84 | STAT3 (0.52) | ALDH1A1STAT3LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | TSHR 2080/4885HCAR3 1377/4885ALDH1A1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.